421 results on '"Carson, Peter"'
Search Results
2. Land application of industrial wastes: impacts on soil quality, biota, and human health
3. Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping
4. Abstract 12936: Quality of Life Assessments as Inclusion Criteria in Heart Failure Clinical Trials
5. Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus
6. Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial
7. Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy
8. Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction
9. Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory
10. Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2
11. Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium
12. Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials
13. Covariate adjusted reanalysis of the I-Preserve trial
14. Design of a “Lean” Case Report Form for Heart Failure Therapeutic Development
15. Beta-blocker Use and 30-day All-cause Readmission in Medicare Beneficiaries with Systolic Heart Failure
16. CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy: 10-Year Follow-Up of the STICH Trial
17. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction
18. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction
19. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial
20. A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation
21. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial
22. Persistence of 123I-mIBG Prognostic Capability in Relation to Medical Therapy in Heart Failure (from the ADMIRE-HF Trial)
23. Safety, Performance, and Efficacy of Cardiac Contractility Modulation Delivered by the 2-Lead Optimizer Smart System: The FIX-HF-5C2 Study
24. Sex-Related Differences in Heart Failure With Preserved Ejection Fraction
25. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status
26. Heart Failure in Non-Caucasians, Women, and Older Adults: A White Paper on Special Populations From the Heart Failure Society of America Guideline Committee
27. Advanced (Stage D) Heart Failure: A Statement From the Heart Failure Society of America Guidelines Committee
28. Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro–B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction
29. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction)
30. The STICH Trial (Surgical Treatment for Ischemic Heart Failure): Mode-of-Death Results
31. Acute Decompensated Heart Failure: Update on New and Emerging Evidence and Directions for Future Research
32. Association Between Bilirubin and Mode of Death in Severe Systolic Heart Failure
33. Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting: Results From the STICH Randomized Clinical Trial (Surgical Treatment for Ischemic Heart Failure)
34. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction)
35. Update on Aldosterone Antagonists Use in Heart Failure With Reduced Left Ventricular Ejection Fraction Heart Failure Society of America Guidelines Committee
36. Indications for Cardiac Resynchronization Therapy: 2011 Update From the Heart Failure Society of America Guideline Committee
37. Subgroup Analysis of a Randomized Controlled Trial Evaluating the Safety and Efficacy of Cardiac Contractility Modulation in Advanced Heart Failure
38. Influence of Global Region on Outcomes in Heart Failure Beta-Blocker Trials
39. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure
40. Mode of Death and Hospitalization from the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) Trial and Comparison of Clinical Events Committee Adjudicated Versus Investigator Reported Outcomes
41. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: Results from efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) program
42. Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure
43. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response
44. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study
45. Emotions and identity in the figured world of becoming a doctor
46. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction
47. Relationship of Quality of Life Scores With Baseline Characteristics and Outcomes in the African-American Heart Failure Trial
48. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction
49. The Safety of an Adenosine A1-Receptor Antagonist, Rolofylline, in Patients with Acute Heart Failure and Renal Impairment: Findings from PROTECT
50. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.